The discussion traces the evolution of their scientific mission from broad philanthropy to a focused push on AI-driven biomedical discovery. Central to this vision is the Biohub, where interdisciplinary teams are building comprehensive models of cells and the immune system by integrating vast biological datasets with cutting-edge AI. A major bottleneck remains data acquisition, prompting investments in high-resolution imaging and custom-built microscopes to digitize biological structures at scale. AI models like rbio1 and VariantFormer are being trained on this data to simulate cellular behavior, test hypotheses, and accelerate research that was once limited by wet lab experimentation. The team emphasizes open science, collaboration, and computational modeling as key to de-risking bold research. With the integration of Evolutionary Scale’s protein modeling expertise, they aim to scale discovery and develop a virtual immune system capable of engineering immune cells for precise disease intervention. Ultimately, the goal is to shift medicine from reactive to proactive—enabling early detection, personalized treatments, and a future where curing all diseases is grounded in data, models, and cross-disciplinary innovation.